Ian Cruickshanks from the South African Institute of Race Relations chose Long4Life as his stock pick of the day and Nic Norman-Smith from Lentus Asset Management chose Gilead Sciences. Cruickshanks said Long4Life was for those who could afford it and had time of their side, “not for the widows and orphans but for the more adventurous investor”. “Does [Long4Life CEO] Brian Joffe have the right recipe going ahead? His record speaks for itself and the capital values will probably add up over the next two to three years.” Norman-Smith said that Gilead Sciences had been the world leader in HIV drugs. “When someone contracts the virus, they have to take a regimen of around 25 different pills and Gilead got this down to around two or they. They have around 85% of the HIV market which is a wonderful market because you can cure people and they can live an absolutely normal life. But they do need their drugs on a continuous basis — so everyone wins.”
OR LISTEN TO THE AUDIO:..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.